Maternal characteristics of patients with relapsed lymphoma during pregnancy
| . | All patients N = 23 . |
|---|---|
| Diagnosis | |
| Hodgkin lymphoma | 18 (78) |
| PTCL∗ | 2 (9) |
| Diffuse large B-cell lymphoma | 1 (2) |
| Follicular lymphoma | 1 (2) |
| Marginal zone lymphoma | 1 (2) |
| Race/ethnicity | |
| White | 19 (82) |
| Hispanic | 1 (4.5) |
| Black | 1 (4.5) |
| American Indian | 1 (4.5) |
| Asian | 1 (4.5) |
| Previous therapy for initial lymphoma† | ABVD 13 (57%), other multiagent chemotherapy 3 (13%), BEACOPP 2 (9%), MACOP-B 2 (9%), and 1 each bendamustine/ obinutuzimab, R-CHOP, and radiotherapy |
| Median age at relapse, y | 31 (21-35) |
| Parity | |
| P0 | 9 (39) |
| P1 | 10 (43) |
| P2 | 4 (18) |
| Stage at relapse | |
| I | 3 (13) |
| II | 10 (44) |
| III | 4 (17) |
| IV | 4 (17) |
| B symptoms | 12 (53) |
| Anemia‡ | 9 (39) |
| Thrombocytopenia§ | 1 (4) |
| Lactase dehydrogenase|| | |
| Increased | 7 (30) |
| Normal | 8 (35) |
| Transplant after pregnancy¶ | |
| Autologous | 6 (31.6) |
| Allogeneic | 3 (15.8) |
| . | All patients N = 23 . |
|---|---|
| Diagnosis | |
| Hodgkin lymphoma | 18 (78) |
| PTCL∗ | 2 (9) |
| Diffuse large B-cell lymphoma | 1 (2) |
| Follicular lymphoma | 1 (2) |
| Marginal zone lymphoma | 1 (2) |
| Race/ethnicity | |
| White | 19 (82) |
| Hispanic | 1 (4.5) |
| Black | 1 (4.5) |
| American Indian | 1 (4.5) |
| Asian | 1 (4.5) |
| Previous therapy for initial lymphoma† | ABVD 13 (57%), other multiagent chemotherapy 3 (13%), BEACOPP 2 (9%), MACOP-B 2 (9%), and 1 each bendamustine/ obinutuzimab, R-CHOP, and radiotherapy |
| Median age at relapse, y | 31 (21-35) |
| Parity | |
| P0 | 9 (39) |
| P1 | 10 (43) |
| P2 | 4 (18) |
| Stage at relapse | |
| I | 3 (13) |
| II | 10 (44) |
| III | 4 (17) |
| IV | 4 (17) |
| B symptoms | 12 (53) |
| Anemia‡ | 9 (39) |
| Thrombocytopenia§ | 1 (4) |
| Lactase dehydrogenase|| | |
| Increased | 7 (30) |
| Normal | 8 (35) |
| Transplant after pregnancy¶ | |
| Autologous | 6 (31.6) |
| Allogeneic | 3 (15.8) |
ABVD, doxorubicin, bleomycin, vinblastine sulfate, and dacarbazine; BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone; MACOP-B: methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin; PTCL, peripheral T-cell lymphoma; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone.
Data are presented as number (percentage) or median (interquartile range).
One case each: PTCL not otherwise specified and ALK–negative anaplastic large-cell lymphoma.
Two patients with Hodgkin lymphoma had also received previous ifosfamide-based therapy (post-ABVD) followed by autologous transplantation.
Data available for n = 22.
Data available for n = 21.
Data available for n = 15.
Data available for n = 19.